Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
AssigneesMitobridge, Inc., The Salk Institute for Biological Studies
InventorsMichael Downes, Ronald M. Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
Claims23
1-5. (canceled)
A compound having the structure of Formula (Ibb):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is hydrogen, halogen, —C1-C4-alkyl, —C1-C4-haloalkyl, —CN, —C1-C4-alkoxy, —C1-C4-haloalkoxy, or —C3-C6-cycloalkyl;
- R2 is hydrogen, halogen, —CN, —C1-C4-alkyl, —C1-C4-haloalkyl, —C3-C6-cycloalkyl, —C1-C4-alkoxy, —C1-C4-haloalkoxy, —S (C1-C4-alkyl), —SO2(C1-C4-alkyl), 5- or 6-membered heterocyclyl, aryl, 5-membered heteroaryl, —≡—R2A, —O(CH2)mR2B, —NH(C1-C4-alkyl), —N(C1-C4-alkyl)2, or —C(O)(C1-C4-alkyl), wherein aryl and heteroaryl are optionally substituted with halogen, —OH, —CN, C1-C4-alkyl, formyl, acetyl, acetoxy, or carboxy, and wherein m is an integer having value of 1, 2, or 3;
- R2A and R2B are each independently —C1-C4-alkyl, —C1-C4-haloalkyl, or —C3-C6-cycloalkyl;
- each R20 is independently hydrogen, halogen, —C1-C4-alkyl, —CN, or —C1-C4-alkoxy;
- and
- x is an integer having a value of 1 or 2.
(canceled)
(R)-3-methyl-6-(2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid, or a pharmaceutically acceptable salt thereof.
22-24. (canceled)
Dependencies are inferred from the claim text.